European Commission (2003). Proposal for a Regulation of the European Parliament and of the Council Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Establishing a European Chemicals Agency and Amending Directive 1999/45/EC and Regulation (EC) {on persistent Organic Pollutants} and Proposal for a Directive of the European Parliament and on the Council Amending Council Directive 67/548/EEC in Order to Adapt it to Regulation (EC) of the European Parliament and on the Council Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals, COM(2003) 644 final, 158 pp. Brussels, Belgium: European Commission. Website http://europa.eu.int/eur-lex/en/com/pdf/2003/com2003_0644en.html (Accessed 2.02.06).
3.
Anon. (2003). Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products (Text with EEA relevance). Official Journal of the European UnionL66, 26–35.
4.
SetzerR.W., & KimmelC.A. (2003). Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances. Pure and Applied Chemistry75, 2151–2158.
5.
JohannsenF.R. (1990). Risk assessment of carcinogenic and non-carcinogenic chemicals. Critical Reviews in Toxicology20, 341–367.
6.
CrumpK. (2002). Critical issues in benchmark calculations from continuous data. Critical Reviews in Toxicology32, 133–153.
7.
WorthA.P., & BallsM., eds. (2002). Alternative (non-animal) methods for chemicals testing: current status and future prospects. A report prepared by ECVAM and the ECVAM working group on chemicals. ALTA30, Suppl. 1, 71.
8.
BlaauboerB.J., ForsbyA., HoustonJ.B., BeckmanM., CombesR.D., & DeJonghJ. (2000). An integrated approach to the prediction of systemic toxicity using biokinetic models and biological in vitro test methods. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (eds. BallsM., Van ZellerA.M., & HalderM.E.), pp. 525–536. Amsterdam, The Netherlands: Elsevier.
9.
De KanterR., MonshouwerM., DraaismaA.L., De JagerM.H., de GraafI.A., ProostJ.H., MeijerD.K., & GroothuisG.M. (2004). Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon. Xenobiotica34, 229–241.
10.
TreijtelN., BarendregtA., FreidigA.P., BlaauboerB.J., & van EijkerenJ.C.H. (2004). Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition32, 884–891.
11.
TreijtelN., van HelvoortH., BarendregtA, BlaauboerB.J., & van EijkerenJ.C. (2005). The use of sandwich-cultured rat hepatocytes to determine the intrinsic clearance of compounds with different extraction ratios: 7-ethoxycoumarin and warfarin. Drug Metabolism and Disposition33, 1325–1332.
12.
van der ValkJ., MellorD., BrandsR., FischerR., GruberF., GstraunthalerG., HellebrekersL., HyllnerJ., JonkerF.H., PrietoP., ThalenM., & BaumansV. (2004). The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicology in Vitro18, 1–12.
13.
SpielmannH., BochkovN.P., CostaL., GribaldoL., GuillouzoA., HeindelJ.J., KarolM., ParchmentR., PfallerW., Prieto-PeraitaP., & ZacharewskiT. (1998). Alternative testing methodologies for organ toxicity. Environmental Health Perspectives106, Suppl. 2, 427–441.
14.
PfallerW., BallsM., ClothierR., CoeckeS., DierickxP., EkwallB., HanleyB.A., HartungT., PrietoP., RyanM., SchmuckG., SladowskiD., VericatJ.A., WendelA., WolfA., & ZimmerJ. (2001). Novel advanced in vitro methods for long term toxicity testing. The report and recommendations of ECVAM workshop 45. ATLA29, 393–426.
VickersA.E., & FisherR.L. (2004). Organ slices for the evaluation of human drug toxicity. Chemico-Biological Interactions32, 577–590.
17.
BaderA., RinkesI.H., ClossE.I., RyanC.M., TonerM., CunninghamJ.M., TompkinsR.G., & YarmushM.L. (1992). A stable long-term hepatocyte culture system for studies of physiologic processes: cytokine stimulation of the acute phase in rat and human hepatocyte. Biotechnology Progress8, 219–225.
18.
LorealO., LevavasseurF., FromagetC., GrosD., GuillouzoA., & ClementB. (1993). Cooperation of Ito cells and hepatocytes in the deposition of an extracellular matrix in vitro.American Journal of Pathology143, 538–544.
19.
CoeckeS., RogiersV., BaylissM., CastellJ., DoehmerJ., FabreG., FryJ., KernA., & WestmorelandC. (1999). The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: the current status. ATLA27, 597–638.
20.
HartungT. (2001). Summary: EU Standards measurements and testing projects PL95-3407. Development of a standardised in vitro methodol-ogy for hepatic and renal toxicity testing. ATLA29, 493–495.
21.
GebhardtR., HengstlerJ.G., MullerD., GlocknerR., BuenningP., LaubeB., SchmelzerE., UllrichM., UteschD., HewittN., RingelM., HilzB.R., BaderA., LangschA., KooseT., BurgerH.J., MaasJ., & OeschF. (2003). New hepatocyte in vitro system for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operating procedures. Drug Metabolism Reviews35, 145–213.
22.
DuffT., CarterS., FeldmanG., McEwanG., PfallerW., RhodesP., RyanM., & HawksworthG. (2002). Transepithelial resistance and inulin permeability as endpoints in in vitro nephrotoxicity testing. ATLA30, 53–59.
23.
Le FerrecE., ChesneC., ArtussonP., BraydenD., FabreG., GiresP., GuillouF., RoussetM., RubasW., & ScarinoM.A. (2001). In Vitro Models of the Intestinal Barrier. The report and recommendations of ECVAM workshop 46. ATLA29, 649–668.
24.
SambuyY., De AngelisI., RanaldiG., ScarinoM.L., StammatiA., & ZuccoF. (2005). The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biology and Toxicology21, 1–26.
25.
HilgendorfC., Spahn-LangguthH., RegardhC.G., LipkaE., AmidonG.L., & LangguthP. (2000). Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. Journal of Pharmaceutical Sciences89, 63–75.
26.
PintoM., AppayM.D., Simon-AssanP., ChevalierG., DracopoliN., FoghJ., & ZweibaumA. (1982). Enterocytic differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium. Biology of the Cell47, 193–196.
27.
BehrensI., StenbergP., ArturssonP., & KisselT. (2001). Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharmaceutical Research18, 1138–1145.
28.
DobbsL.G., PianM.S., MaglioM., DumarsS., & AllenL. (1997). Maintenance of the differentiated type II cell phenotype by culture with an apical air surface. American Journal of Physiology273, L347–54.
29.
GindorfC., SteimermA., LehrC.M., BockU., SchmitzS., & HaltnerE. (2001). Marker transport across biological barriers in vitro: comparison of cell culture models for the gastrointestinal barrier, the blood–brain barrier and the alveolar epithelium of the lung. ALTEX18, 155–164.
30.
DietlP., HallerT., MairN., & FrickM. (2001). Mechanisms of surfactant exocytosis in alveolar type II cells in vitro and in vivo.News in Physiological Sciences16, 239–243.
31.
JenningsP., BertocchiC., FrickM., HallerT., PfallerW., & DietlP. (2005). Ca2+ induced surfactant secretion in alveolar type II cultures isolated from the H-2Kb-tsA58 transgenic mouse. Cellular Physiology and Biochemistry15, 159–166.
32.
ZuangV., AlonsoM-A., BothamP.A., EskesC., FentemJ., LiebschM., & van de SandtJ.J.M. (2005). Skin irritation and corrosion. ATLA33, Suppl. 1, 35–46.
33.
HarryG.J., BillingsleyM.L., BruininkA., CampbellI.L., ClassenW., DormanD.C., GalliC., RayD., SmithR.A., & TilsonH.A. (1998). In vitro techniques for the assessment of neurotoxicity. Environmental Health Perspectives106S, 131–158.
34.
SchmuckG., AhrH.J., & SchluterG. (2000). Rat cortical neuron cultures: an in vitro model for differentiating mechanisms of chemically induced neurotoxicity. In Vitro and Molecular Toxicology13, 37–50.
35.
ForsbyA., PilliF., BianchiV., & WalumE. (1995). Determination of critical cellular neurotoxic concentrations in human neuroblastoma (SH-SY5Y) cell cultures. ATLA23, 800–811.
36.
SchmuckG., & AhrH. (1997). Improved in vitro method for screening organophosphate-induced delayed polyneuropathy. Toxicology in Vitro11, 263–270.
37.
NorenbergM.D. (1996). Astrocytosis. In The Role of Glia in Neurotoxicology (ed. AschnerM., & KimelbergH.K.), pp. 93–110. Boca Raton, FL, USA: CRC Press.
38.
GoldoniM., VettoriM.V., AlinoviR., CaglieriA., CeccatelliS., & MuttiA. (2003). Models of neurotoxicity: extrapolation of benchmark doses in vitro.Risk Analysis23, 505–514.
39.
DengW., & PoretzR.D. (2003). Oligodendroglia in developmental neurotoxicity. Neurotoxicology24, 161–178.
40.
HanischU.K. (2002). Microglia as a source and target of cytokines. Glia40, 140–155.
41.
HoneggerP., & Monnet-TschudiF. (2001). Aggregating neural cell cultures. In Protocols for neural cell culture, (ed. FedoroffS., & RichardsonA.), 3rd edn, pp. 199–218, Totowa, NJ, USA: Humana Press.
42.
ZurichM.G., LengacheS., BraissantO., Monnet-TschudiF., PellerinL., & HoneggerP. (2005). Unusual astrocyte reactivity caused by the food mycotoxin ochratoxin A in aggregating rat brain cell cultures. Neuroscience134, 771–782.
43.
AdamchikY., FrantsevaM.V., WeisspapirM., CarlenP.L., & Perez VelazquezJ.L. (2000). Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Research Protocols5, 153–158.
44.
NorabergJ., GramsbergenJ.B.P., FonnumF., & ZimmerJ. (1998). Trimethyltin (TMT) neurotoxicity in organotypic rat hippocampal slice cultures. Brain Research783, 305–315.
45.
PringleA.K., SchmidtW., DeansJ.K., WulfertE., ReymannK.G., & SundstromL.E. (2003). 7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro.European Journal of Neuroscience18, 117–124.
46.
NorabergJ. (2004). Organotypic brain slice cultures: An efficient and reliable method for neurotoxicological screening and mechanistic studies. ATLA32, 329–337.
47.
MetcalfD. (1984). The basic biology of haemopoiesis. In The Haemopoietic Colony Stimulating Factors (ed. MetcalfD.), pp. 1–26. Amsterdam, The Netherlands: Elsevier.
48.
SachsL. (1987). The molecular control of blood cell development. Science, New York238, 1374–1379.
49.
GardnerR.V., McKinnonE., & AstleC.M. (2001). Analysis of the stem cell sparing properties of cyclophosphamide. European Journal of Haematology67, 14–22.
50.
NebenS., MarcusK., & MauchP. (1993). Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood81, 1960–1967.
51.
TestaN., & MolineuxG., eds. (1993). Haemopoiesis. A Practical Approach.317 pp. New York, NY, USA: Oxford University Press.
52.
LemieuxM.E., RebelV.I., LansdorpP.M., & EavesC.J. (1995). Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow “switch” cultures. Blood86, 1339–1347.
53.
PloemacherR.E., van der SluijsJ.P., VoermanJ.S., & BronsN.H. (1989). An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood74, 2755–2763.
54.
LarochelleA., VormoorJ., HanenbergH., WangJ.C.Y., BathiaM., LapidotT., MoritzT., MurdochB., Li XiaoX., KatoI., WilliamsD.A., & DickJ.E. (1996). Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nature Medicine2, 1329–1337.
55.
WildingI.R., & BellJ.A. (2005). Improved early clinical development through human microdosing studies. Drug Discovery Today10, 890–894.
56.
DierickxP.J., & EkwallB. (1992). Long-term cytotoxicity testing of the first twenty MEIC chemicals by the determination of the protein content in human embryonic lung cells. ATLA20, 285–289.
57.
DierickxP.J., & EkwallB. (1993). Long-term cytotoxicity testing of the MEIC chemicals 21–50 by determination of the protein content in human embryonic lung cells. ALTEX2, 33–36.
58.
EkwallB., CledmensonC., EkwallC., RingP., & RomertL. (1999). EDIT: a new international multicentre programme to develop and evaluate batteries of in vitro tests for acute and chronic systemic toxicity. ATLA27, 339–349.
59.
CookJ.R., CruteB.E., PatroneL.M., GabrielsJ., LaneM.E., & Van BuskirkR.G. (1989). Microporosity of the substratum regulates differentiation of MDCK cells in vitro.In Vitro Cell and Developmental Biology25, 914–922.
60.
ZlatkineP., MolL.G., LoiseauA., & le GrimellecC. (1993). Transport of choline by Madi.Darby canine kidney cells. Biochimica et Biophysica Acta1153, 237–242.
61.
LangM.A., MullerJ., PrestonA.S., & HandlerJ.S. (1986). Complete response to vasopressin requires epithelial organization in A6 cells in culture. American Journal of Physiology250, C138–145.
62.
MinuthW.W., DermietzelR., KlothS., & HennerkesB. (1992). A new method culturing renal cells under permanent superfusion and producing a luminal-basal medium gradient. Kidney International41, 215–219.
63.
FelderE., JenningsP., SeppiT., & PfallerW. (2002). LLC-PK1 cells maintained in a new perfusion cell culture system exhibit an improved oxidative metabolism. Cellular Physiology and Biochemistry12, 153–162.
64.
GramsbergenJ.B., Leegsma-VogtG., VenemaK., NorabergJ., & KorfJ. (2003). Quantitative on-line monitoring of hippocampus glucose and lactate metabolism in organotypic cultures using biosensor technology. Journal of Neurochemistry85, 399–408.
65.
PfallerW., JenningsP., LechleitnerT., & AbbergerT. (2005). A novel perfusion cell culture system for acute, repeat dose and long term toxicity testing. ALTEX22, Special Issue, 337.
66.
SidoliF.R., MantalarisA., & AspreyS.P. (2004). Modelling of mammalian cells and cell culture processes. Cytotechnology44, 27–46.
67.
AbbergerT., JenningsP., & PfallerW. (2005). Evaluation of perfusion culture for investigating the toxic effects of cadmium chloride to two renal epithelial cell lines. ALTEX22, Special Issue, 324.
68.
JakobsenB., & ZimmerJ. (2001). Chronic exposure of kainate and NBQX changes AMPA toxicity in hippocampal slice cultures. Neuroreport12, 3593–3597.
MullerM., RietschinL., GroggF., StreitP., & GähwilerB.H. (1994). Selective degeneration of CA1 pyramidal cells by chronic application of bismuth. Hippocampus4, 204–209.
71.
HanleyA.B., McBridgeJ., OehlschlagerS., & OpraE. (1999). Use of a flow bioreactor as a chronic toxicity model system. Toxicology in Vitro13, 847–851.
72.
PazosP., FontanerS., & PrietoP. (2002). Long term in vitro toxicity models: comparisons between a flow cell bioreactor, a static cell bioreactor, and static cell cultures. ATLA30, 515–523.
73.
HartungT., BallsM., BardouilleC., BlanckO., CoeckeS., GstraunthalerG., & LewisD. (2002). Good Cell Culture Practice. ECVAM Good Cell Culture Practice Task Force Report 1. ATLA30, 407–414.
74.
CoeckeS., BallsM., BoweG., DavisJ., GstraunthalerG., HartungT., HayR., MertenO.W., PriceA., SchechtmanL., GlynS., & StokesB. (2005). Guidance on good cell culture practice. A report of the second ECVAM Task Force on good cell culture practice. ATLA33, 261–287.
75.
DonadioC., TramontiG., LucchesiA., GiordaniR., LucchettiA., & BianchiC. (1998). Gamma-glutamyltranspeptidase is a reliable marker for tubular effects of contras media. Renal Failure20, 319–324.
76.
KiltyC., DoyleS., HassettB., & ManningF. (1998). Glutathione S-transferases as biomarkers of organ damage: applications of rodent and canine GST enzyme immunoassays. Chemico-Biological Interactions111-112, 123–135.
77.
PfallerW., ThorwartlU., Nevinny-StickelM., KrallM., SchoberM., JoannidisM., & HobischA. (1994). Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury. Kidney International, 47, S68–S75.
78.
SlatteryC., CampbellE., McMorrowT., & RyanM.P. (2005). Cyclosporine a-induced renal fibrosis: a role for epithelial-mesenchymal transition. American Journal of Pathology167, 395–407.
79.
KarpN.A., GriffinJ.L., & LilleyK.S. (2005). Application of partial least squares discriminant analysis to two-dimensional difference gel studies in expression proteomics. Proteomics5, 81–90.
80.
HoogC.L., & MannM. (2004). Proteomics. Annual Review of Genomics and Human Genetics5, 267–293.
81.
LindonJ.C., HolmesE., & NicholsonJ.K. (2001). Pattern recognition methods and applications in biomedical magnetic resonance. Progress in Nuclear Magnetic Resonance39, 1–40.
82.
ValafarF. (2002). Pattern recognition techniques in microarray data analysis. Annals of the New York Academy of Science980, 41–64.
83.
ErikssonL., JohanssonE., Kettaneh-WoldN., & WoldS. (1999). Introduction to Multi- and Megavariate Data Analysis using Projection Methods (PCA & PLS), 490 pp. Umea, Sweden: Umetrics Academy.
84.
GriffinJ.L. (2003). Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Current Opinion in Chemical Biology7, 648–654.
85.
WilsonI.D., PlumbR., GrangerJ., MajorH., WilliamR., & LenzE.M. (2005). HPLC-MS-based methods for the study of metabonomics. Journal of Chromatography817, 67–76.
86.
RobertsonD.G. (2005). Metabonomics in toxicology: a review. Toxicological Science85, 809–822.
87.
ValetG. (2005). Human cytome project, cytomics, and systems biology: The incentive for new horizons in cytometry. Journal of the International Society of Analytical Cytology: Cytometry Part A64, 1–2.
88.
HealyE., DempseyM., LallyC., & RyanM.P. (1998). Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney International54, 1955–1966.
89.
Alvarez-BarrientosA., O'ConnorJ.E., Nieto CastilloR., Moreno MorenoA.B., & PrietoP. (2001). Use of flow cytometry and confocal microscopy techniques to investigate early CdCl(2)-induced nephrotoxicity in vitro.Toxicology in Vitro15, 407–412.
90.
O'ConnorJ.E., MartinezA., CastellJ.V., & Gomez-LechonM.J. (2005). Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. The Journal of the International Society of Analytical Cytology: Cytometry Part A63, 48–58.
91.
StriggowF., RöhnertP., & ReymannK. (2002). Telomics: Tissue-based screening for target validation and preclinical drug development. New Drugs1, 30–36.
92.
LeightonJ.K. (2005). Application of emerging technologies in toxicology and safety assessment: regulatory perspectives. International Journal of Toxicology24, 153–155.
93.
RajpalD.K. (2005). Understanding biology through bioinformatics. International Journal of Toxicology24, 147–152.
94.
BalbusJ.M. (2005). Ushering in the new toxicology: toxicogenomics and the public interest. Environmental Health Perspectives113, 818–22.
95.
GriffinJ.L., BonnetS.A., MannC., HebbachiA.M., GibbonsG.F., NicholsonJ.K., ShouldersC.C., & ScottJ. (2004). An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiological Genomics17, 140–149.
96.
MoggsJ.G., MurphyT.C., LimF.L., MooreD.J., StuckeyR., AntrobusK., KimberI., & OrphanidesG. (2005). Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. Journal of Molecular Endocrinology34, 535–551.
97.
HeijneW.H., KienhuisA.S., van OmmenB., StierumR.H., & GrotenJ.P. (2005). Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Review of Proteomics2, 767–780.
98.
WoodwardK.N. (2005). Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies. Journal of Veterinary Pharmacology and Therapeutics28, 213–231.
99.
WoodwardK. (2004). The evolution of safety assessments for veterinary medicinal products in the European Union. Veterinary and Human Toxicology46, 199–205.
100.
FAO/WHO (2004). Evaluation of certain veterinary drug residues in food. Sixty-second report of the Joint FAO/WHO Expert Committee on food additives. World Health Organisation Technical Report Series, No. 925, pp. 1–72. Geneva, Switzerland: WHO.
101.
AndersenM.E. (2003). Toxicokinetic modeling and its applications in chemical risk assessment. Toxicology Letters138, 9–27.
102.
BlaauboerB.J. (2002). The applicability of in vitro-derived data in hazard identification and characterisation of chemicals. Environmental Toxicology and Pharmacology11, 213–225.
103.
BlaauboerB.J. (2002). The necessity of biokinetic information in the interpretation of in vitro toxicity data. ATLA30, 85–91.
104.
LeungH.W. (1991). Development and utilization of physiologically based models for toxicological applications. Journal of Toxicology and Environmental Health32, 247–267.
105.
BrownR.P., DelpM.D., LindstedtS.L., RhombergL.R., & BelilesR.P. (1997). Physiological parameter values for PBPK models. Toxicology and Industrial Health13, 407–484.
106.
AndersenM.E. (1991). Physiological modelling of organic compounds. Annals of Occupational Hygiene35, 309–321.
107.
ClewellH.J., & AndersenM.E. (1986). A multiple dose-route physiological model for volatile chemicals using ACSL/PC. In Languages for Continuous Simulation (ed. CellierF.D.), pp. 95–110. San Diego, CA, USA: Society for Computer Simulation.
108.
KaoJ., PattersonK., & HallJ. (1985). Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: an in vitro study with benzo(a)pyrene and testosterone. Toxicology and Applied Pharmacology81, 502–516.
109.
ArturssonP., & KarlssonJ. (1991). Correlation between oral drug absorption in humans an apparent drug permeability coefficients in human intestinal epithelial (CACO-2) cells. Biochemical and Biophysical Research Communications175, 880–885.
110.
FriendD.R. (1992). In vitro skin permeation techniques. Journal of Controlled Release18, 235–248.
111.
HirohashiT., SuzukiH., ChuX-Y., TamaiI., TsujiA., & SugiyamaY. (2000). Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). Journal of Pharmacology and Experimental Therapeutics292, 265–270.
112.
AustelV., & KutterE. (1983). Absorption, distribution and metabolism of drugs. In Quantitative-structure activity relationships of drugs (ed. ToplissJ.G.), pp. 437–496. New York, NY, USA: Academic Press.
113.
McDougalJ.N., JepsonG.W., ClewellH.J., GargasM.L., & AndersenM.E. (1990). Dermal absorption of organic chemical vapours in rats and humans. Fundamental and Applied Toxicology14, 299–308.
114.
ClarkD.E. (1999). Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. Journal of Pharmaceutical Sciences88, 807–814.
115.
Fiserova-BergerovaV., & DiazM.L. (1986). Determination and prediction of tissue–gas partition coefficients. International Archives of Occupational and Environmental Health58, 75–87.
116.
PacificiG.M., & VianiA. (1992). Methods of determining plasma and tissue binding of drugs. Clinical Pharmacokinetics23, 449–468.
117.
JepsonG.W., HooverD.K., BlackR.K., McCaffertyJ.D., MahleD.A., & GearhartJ.M. (1994). A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundamental and Applied Toxicology22, 519–524.
118.
PoulinP., & KrishnanK. (1995). A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals. Human and Experimental Toxicology14, 273–280.
119.
PoulinP., & KrishnanK. (1995). An algorithm for predicting tissue:blood partition coefficients of organic chemicals from n-octanol:water partition coefficient data. Journal of Toxicology and Environmental Health46, 101–113.
120.
PoulinP., & KrishnanK. (1996). A tissue composition-based algorithm for predicting tissue:air partition coefficients or organic chemicals. Toxicology and Applied Pharmacology136, 126–130.
121.
PoulinP., & KrishnanK. (1996). A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicology and Applied Pharmacology136, 131–137.
122.
DeJonghJ., VerhaarH.J., & HermensJ.L. (1997). A quantitative property–property relationship (QPPR) approach to estimate in vitro tissue–blood partition coefficients of organic chemicals in rats and humans. Archives of Toxicology72, 17–25.
123.
DeJonghJ., VerhaarH.J., & HermensJ.L. (1998). Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). Toxicological Sciences45, 26–32.
124.
PrietoP., BlaauboerB.J., de BoerA.G., BoveriM., CecchelliR., ClemedsonC., CoeckeS., ForsbyA., GallaH-J., GarbergP., GreenwoodJ., PriceA., & TähtiH. (2004). Blood–brain barrier in vitro models and their application in toxicology. The report and recommendations of ECVAM workshop 49. ATLA32, 37–50.
125.
GarbergP., BallsM., BorgN., CecchelliR., FenartL., HurstR.D., LindmarkT., MabondzoA., NilssonJ.E., RaubT.J., StanimirovicD., TerasakiT., ObergJ.O., & OsterbergT. (2005). In vitro models for the blood–brain barrier. Toxicology in Vitro19, 299–334.
126.
GearhartJ.M., JepsonG.W., ClewellH., AndersenM.E., & ConollyR.B. (1990). Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropyl-fluorophosphate. Toxicology and Applied Pharmacology106, 295–310.
127.
CarlileD.J., ZomorodiK., & HoustonJ.B. (1997). Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metabolism and Disposition25, 903–911.
128.
HoustonJ.B., & CarlileD.J. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews29, 891–922.
129.
HoustonJ.B., & CarlileD.J. (1997). Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models. Toxicology in Vitro11, 473–478.
130.
FlintO.P. (1990). In vitro toxicity testing: purpose, validation and strategy. ATLA18, 11–18.
131.
BlaauboerB.J., WortelboerH.M., & MennesW.C. (1990). The use of liver cell cultures derived from different mammalian species in in vitro toxicological studies: implementation in extrapolation models?ATLA18, 251–258.
132.
FrazierJ.M. (1992). In vitro Toxicity Testing: Applications to Safety Evaluation. (ed. FrazierJ.M.), 312 pp. New York, NY, USA: Marcel Dekker Inc.
133.
EskesC., & ZuangV., eds. (2005). Alternative (non-animal) methods for cosmetic testing: current status and future prospects. A report prepared in the context of the 7th Amendment of the Cosmetic Directive for establishing timetables for phasing out animal testing. ATLA33, Suppl. 1, 1–228.
134.
BlaauboerB.J., BarrattM.D., & HoustonJ.B. (1999). The integrated use of alternative methods in toxicological risk evaluation. ECVAM Integrated Testing Strategies Task Force Report 1. ATLA27, 229–237.
135.
Gubbels-van HalW.M., BlaauboerB.J., BarentsenH.M., HoitinkM.A., MeertsI.A., & van der HoevenJ.C. (2005). An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. Regulatory Toxicology and Pharmacology42, 284–295.
136.
GuldenM., MorchelS., & SeibertH. (2001). Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. Toxicology in Vitro15, 233–243.
137.
GuldenM., MorchelS., TahanS., & SeibertH. (2002). Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro.Toxicology175, 201–213.
138.
GuldenM., & SeibertH. (2003). In vitro–in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro.Toxicology189, 211–222.
139.
GuldenM., MorchelS., & SeibertH. (2003). Serum albumin binding at cytotoxic concentrations of chemicals as determined with a cell proliferation assay. Toxicology Letters137, 159–168.
140.
SeibertH., MorchelS., & GuldenM. (2002). Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicology in Vitro16, 289–297.
141.
HeringaM.B., PastorD., AlgraJ., VaesW.H., & HermensJ.L. (2002). Negligible depletion solidphase microextraction with radiolabeled analytes to study free concentrations and protein binding: an example with [3H]estradiol. Analytical Chemistry74, 5993–5997.
142.
EEC (1967). Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations, and administrative provisions relating to the classification, packaging and labeling of dangerous substances. Official Journal of the European Economic Community196, 1–98.
143.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 8 pp. (Updated in 1995) Paris, France: Organisation for Economic Cooperation and Development.
144.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 410: Repeated Dose Dermal Toxicity: 21/28-day Study, 8 pp. Paris, France: Organisation for Economic Cooperation and Development.
145.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 412: Repeated Dose Inhalation Toxicity: 28-day or 14-day Study, 9 pp. Paris, France: Organisation for Economic Cooperation and Development.
146.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 408: Repeated Dose 90-day Oral Toxicity Study in Rodents, 9 pp. (Updated 1998) Paris, France: Organisation for Economic Cooperation and Development.
147.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 409: Repeated Dose 90-day Oral Toxicity Study in Non-Rodents, 9 pp. (Updated 1998) Paris, France: Organisation for Economic Cooperation and Development.
148.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 411: Subchronic Dermal Toxicity: 90-day Study, 9 pp. (Updated 1998) Paris, France: Organisation for Economic Cooperation and Development.
149.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 413: Subchronic Inhalation Toxicity: 90-day Study, 9 pp. Paris, France: Organisation for Economic Cooperation and Development.
150.
OECD (1981). OECD Guidelines for the Testing of Chemicals, No. 452: Chronic toxicity studies, 14 pp. Paris, France: Organisation for Economic Cooperation and Development.
151.
BehrsingH.P., VickersA.E., & TysonC.A. (2003). Extended rat liver slice survival and stability monitored using clinical biomarkers. Biochemical and Biophysical Research Communications321, 209–213.
152.
UmachandranM., HowarthJ., & IoannidesC. (2004). Metabolic and structural viability of precision-cut rat lung slices in culture. Xenobiotica34, 771–780.
153.
PunzelM., WissinkS.D., MillerJ.S., MooreK.A., LemischkaI.R., & VerfaillieC.M. (1999). The myeloid-lymphoid initiating cell (ML-IC) assay assesses the fate of multipotent human progenitors in vitro.Blood93, 3750–3756.
154.
BernsteinI.D., LearyA.G., AndrewsR.G., & OgawaM. (1991). Blast colony-forming cells and precursors of colony-forming cells detectable in long-term marrow culture express the same phenotype (CD33- CD34+). Experimental Hematology19, 680–682.
EckmannL., FreshneyM., WrightE.G., SproulA., WilkieN., & PragnellI.B. (1988). A novel in vitro assay for murine haematopoietic stem cells. British Journal of Cancer, Suppl. 9, 36–40.